The eyeWatch is the world’s first and only adjustable glaucoma drainage implant. Thanks to the unique and innovative mechanism for glaucoma implant inside the eyeWatch, surgeons finally have the possibility to act on patients IOP, in an efficient, painless, non-invasive way.
Available now in most countries. Contact us for availability.
The eyeWatch can be opened or closed post-operatively, without requiring surgical interventions.
The devices, glaucoma valve and glaucoma tube shunt, can also be set to intermediate degrees of opening for more precise tuning.
The tube of the eyeWatch can be opened or closed post- operatively, without requiring surgical interventions.
The device can also be set to intermediate degrees of opening for more precise tuning.
- Only 0.57mm thick
- Made of long-term implantable PEEK
- Compatible with eyePlate, Baerveldt
The tube of the eyeWatch is only 0.48mm, requiring a smaller needle for chamber entry (25G).
Time needed to perform an adjustment
Time required to reach a new IOP after adjustment
Adjustment is painless for the patient
More than 90% of patients have a successful treatment after 1 year, meaning that their pressure is effectively managed1-2
In average, anti-glaucoma medications are reduced to about 1/3 after 1 year 1-2,4
Central endothelial cell count loss after 1 year1-2
“Being able to continuously modify the aqueous humour drainage from day 1 with the eyeWatch Pen adjustments on the eyeWatch system, offers me that extra confidence of safety for my patients, whilst delivering unparalleled eye pressure lowering, predictably and controllably at every single point of follow up. The eyeWatch truly is a landmark innovation in glaucoma tube surgery for the benefit of our patients and glaucoma treating physicians”.
Chrysostomos Dimitriou, Colchester Eye Centre, United Kingdom
“I have used the eyeWatch for more than 8 years and in more than 300 patients already. I am enthusiastic with the results. It can act on IOP from day one, avoiding hypotony and pressure spikes. The results are truly outstanding.”
André Mermoud, Swiss Visio Montchoisi, Lausanne, Switzerland
“Achieving good pressure reduction without the associated risk of hypotony, the eyeWatch is a giant step forward in glaucoma surgery”.
Leon Au, Royal Eye Hospital, Manchester, United Kingdom
“Titration is the holy grail for glaucoma surgery, to provide an ability to dynamically adjust flow for individual patient needs at specific postoperative time points. The eyeWatch glaucoma shunt, with it’s titratable flow control is a major step forward in protecting from early hypotony while allowing for added IOP reduction as needed.”
Ike Ahmed, Prism Eye Institute, Toronto
PRODUCTS
FOR PHYSICIANS
FOR PATIENTS
ABOUT US
